202 related articles for article (PubMed ID: 18790454)
1. Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease.
Spaapen R; Mutis T
Best Pract Res Clin Haematol; 2008 Sep; 21(3):543-57. PubMed ID: 18790454
[TBL] [Abstract][Full Text] [Related]
2. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
3. Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens.
Hambach L; Spierings E; Goulmy E
Best Pract Res Clin Haematol; 2007 Jun; 20(2):171-87. PubMed ID: 17448955
[TBL] [Abstract][Full Text] [Related]
4. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.
Dickinson AM; Wang XN; Sviland L; Vyth-Dreese FA; Jackson GH; Schumacher TN; Haanen JB; Mutis T; Goulmy E
Nat Med; 2002 Apr; 8(4):410-4. PubMed ID: 11927949
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of cancer through targeting of minor histocompatibility antigens.
Hambach L; Goulmy E
Curr Opin Immunol; 2005 Apr; 17(2):202-10. PubMed ID: 15766682
[TBL] [Abstract][Full Text] [Related]
6. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.
Mutis T; Gillespie G; Schrama E; Falkenburg JH; Moss P; Goulmy E
Nat Med; 1999 Jul; 5(7):839-42. PubMed ID: 10395333
[TBL] [Abstract][Full Text] [Related]
7. Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation.
Mori S; El-Baki H; Mullen CA
Bone Marrow Transplant; 2003 May; 31(10):865-75. PubMed ID: 12748663
[TBL] [Abstract][Full Text] [Related]
8. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
[TBL] [Abstract][Full Text] [Related]
9. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
[TBL] [Abstract][Full Text] [Related]
10. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
Falkenburg JH; Willemze R
Best Pract Res Clin Haematol; 2004 Sep; 17(3):415-25. PubMed ID: 15498713
[TBL] [Abstract][Full Text] [Related]
11. Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.
Chao NJ
Biol Blood Marrow Transplant; 2004 Apr; 10(4):215-23. PubMed ID: 15077220
[TBL] [Abstract][Full Text] [Related]
12. A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution.
Holloway PA; Kaldenhoven N; Kok-Schoemaker HM; Dijk Mv; Otten HG; Tilanus M; Postma S; Mutis T; Lokhorst HM; Bloem AC
Br J Haematol; 2005 Jan; 128(1):73-81. PubMed ID: 15606552
[TBL] [Abstract][Full Text] [Related]
13. The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -A*3303.
Torikai H; Akatsuka Y; Miyazaki M; Tsujimura A; Yatabe Y; Kawase T; Nakao Y; Tsujimura K; Motoyoshi K; Morishima Y; Kodera Y; Kuzushima K; Takahashi T
Br J Haematol; 2006 Aug; 134(4):406-16. PubMed ID: 16822283
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease.
Fontaine P; Roy-Proulx G; Knafo L; Baron C; Roy DC; Perreault C
Nat Med; 2001 Jul; 7(7):789-94. PubMed ID: 11433342
[TBL] [Abstract][Full Text] [Related]
15. Cytolytic pathways in haematopoietic stem-cell transplantation.
van den Brink MR; Burakoff SJ
Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998
[TBL] [Abstract][Full Text] [Related]
16. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
[TBL] [Abstract][Full Text] [Related]
17. Minor transplantation antigens: mouse models for human host-versus-graft, graft-versus-host and graft-versus-leukemia reactions.
Simpson E
Arch Immunol Ther Exp (Warsz); 1998; 46(6):331-9. PubMed ID: 9883311
[TBL] [Abstract][Full Text] [Related]
18. Adoptive cancer immunotherapy: discovering the best targets.
Perreault C; Brochu S
J Mol Med (Berl); 2002 Apr; 80(4):212-8. PubMed ID: 11976730
[TBL] [Abstract][Full Text] [Related]
19. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.
Ueha S; Murai M; Yoneyama H; Kitabatake M; Imai T; Shimaoka T; Yonehara S; Ishikawa S; Matsushima K
J Leukoc Biol; 2007 Jan; 81(1):176-85. PubMed ID: 17053165
[TBL] [Abstract][Full Text] [Related]
20. T cell immunity and graft-versus-host disease (GVHD).
Ichiki Y; Bowlus CL; Shimoda S; Ishibashi H; Vierling JM; Gershwin ME
Autoimmun Rev; 2006 Jan; 5(1):1-9. PubMed ID: 16338205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
